|

Iparomlimab and Tuvonralimab Injection (QL1706) Clinical Trials

3 actively recruiting trials

Also known as: chemotherapy

Pipeline

Phase 2: 2Phase 1/2: 1

Top Sponsors

  • Wang Xin1
  • Nanfang Hospital, Southern Medical University1
  • Hebei Medical University Fourth Hospital1

Indications

  • Cancer3
  • QL17061
  • Type VP3/4 Portal Vein Tumor Thrombosis1
  • RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin1
  • Hepatecellular Carcinoma1

Other3 trials

Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)
Phase 2
PULSAR Combined With Immunotherapy and Chemotherapy
Phase 1/2
QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.